A phase I, placebo controlled, dose escalation safety and pharmacokinetic study of (Z)-Endoxifen in healthy female volunteers
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Endoxifen (Primary) ; Endoxifen (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Atossa Genetics
- 01 Feb 2018 Additional findings from the oral arm of the Endoxifen of this study presented in an Atossa Genetics Media Release.
- 31 Jan 2018 According to a Atossa Genetics media release, additional data from the study will be disscused on a conference call in Feb 2018.
- 25 Oct 2017 According to a Atossa Genetics media release, company will host a conference call to discuss preliminary results from oral Endoxifen arm on 25 Oct 2017.